These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9578169)

  • 1. Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
    Shapiro MA; Sesnie JC; Desaty TM; Griffin TJ; Heifetz CL
    J Antimicrob Chemother; 1998 Mar; 41(3):403-5. PubMed ID: 9578169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
    Pascual A A; Joyanes P; Martínez-Martínez L; del Carmen Conejo M; Hernández G; Chaves J; Perea EJ
    Enferm Infecc Microbiol Clin; 2001 Nov; 19(9):432-4. PubMed ID: 11709121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pseudomonas aeruginosa corneal abscess refractory to fluoroquinolones].
    Díaz Valle D; Alós Cortés JI; Arteaga Sánchez A; Toledano Fernández N; Poza Morales Y; Díaz-Valle T
    Arch Soc Esp Oftalmol; 2002 Jul; 77(7):397-9. PubMed ID: 12098814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.
    Shapiro MA; Dever JA; Sesnie JC; VanderRoest SR
    J Antimicrob Chemother; 1997 Feb; 39(2):273-6. PubMed ID: 9069553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
    Kaneko Y; Yanagihara K; Kuroki M; Ohi H; Kakeya H; Miyazaki Y; Higashiyama Y; Hirakata Y; Tomono K; Kadota JI; Kohno S
    Chemotherapy; 2001 Dec; 47(6):421-9. PubMed ID: 11786657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
    Bakker-Woudenberg IA; ten Kate MT; Guo L; Working P; Mouton JW
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2575-81. PubMed ID: 12121935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal abscess due to Pseudomonas aeruginosa: report of two cases.
    Bampala S; Kollios K; Antachopoulos C; Tratselas A; Roilides E
    Minerva Pediatr; 2013 Jun; 65(3):349-52. PubMed ID: 23685385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.
    Ernst EJ; Hashimoto S; Guglielmo J; Sawa T; Pittet JF; Kropp H; Jackson JJ; Wiener-Kronish JP
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2389-94. PubMed ID: 10508012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of sparfloxacin against experimental renal infections in mice.
    Georgopoulos A; Feistauer SM; Graninger W; Pfleger S; Georgopoulos M
    Antimicrob Agents Chemother; 1992 Feb; 36(2):505-7. PubMed ID: 1318685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
    Jensen H; Zerouala C; Carrier M; Short B
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):36-43. PubMed ID: 15718826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
    Mikuniya T; Kato Y; Ida T; Maebashi K; Monden K; Kariyama R; Kumon H
    J Infect Chemother; 2007 Oct; 13(5):285-90. PubMed ID: 17982715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
    Jung R; Fish DN; Obritsch MD; MacLaren R
    J Hosp Infect; 2004 Jun; 57(2):105-11. PubMed ID: 15183239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa-acquired resistance to imipenem-cilastatin: commentary on clinical implications of antibiotic resistance.
    Tidwell BH; Cleary JD
    Pharmacotherapy; 1993; 13(2):165; discussion 166. PubMed ID: 8469624
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S; Schito AM; Marchese A; Schito GC
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.